SOLICITATION NOTICE
B -- Evaluation of insulin-like growth factor-I plasma biomarkers and multiple myeloma
- Notice Date
- 8/4/2009
- Notice Type
- Presolicitation
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-90162-AV
- Archive Date
- 8/29/2009
- Point of Contact
- Ashley L. Virts,
- E-Mail Address
-
virtsa@mail.nih.gov
(virtsa@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Occupational and Environmental Epidemiology Branch (OEEB) plans to procure on a sole source basis with Jewish General Hospital; Lady David Institute, Pollack Research Lab – E 423; 3755 Cote Ste. Catherine Rd.; Montreal, Quebec H3T 1E2 for services regarding Evaluation of insulin-like growth factor-I plasma biomarkers and multiple myeloma. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1 (b) (1). The North American Industry Classification System Code is 621511 and the business size standard is $13.5M. The NCI Division of Cancer Epidemiology and Genetics (DCEG), Occupational and Environmental Epidemiology Branch (OEEB) is currently investigating whether pre-diagnostic plasma/serum levels of selected insulin-like growth factor-I (IGF-1) pathway biomarkers (IGF¬1., IGF binding protein-1, IGF binding protein-3, C-peptide) are associated with risk of multiple myeloma. Insulin-like growth factor-I is a potent rnitogen in both normal and neoplastic cells. More than 90% of circulating IGF is bound to IGF binding proteins (IGFBP), Metabolic disorders caused by obesity, including hyperinsulinemia, may modulate the elevation of circulating free IGF-1 by down regulating IGFBP-I and -2. Laboratory and in viva studies have demonstrated that bioactive IGF-I has proliferative and antiapoptotic effects on multiple myeloma cells and modulates their migration. These findings collectively suggest that persons with elevated plasma levels of bioavailable IGF-1 may have a higher risk of multiple myeloma. The objective of this project is research involving specimens from nine cohort studies to evaluate the association of biomarkers of bioavailable IGF-1 (i.e., total 16F-1, IGFBP-1, IGFBP-3, and IGF-1:IGFBP-3 molar ratio) and hyperinsulinemia (i.e., C-peptide) with incident multiple rnyeloma to contribute novel information on multiple myeloma etiology. The entire pooling project will involve an estimated total sample size of 560 cases and 1120 controls; two NCI cohorts [the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) and the the Alpha-Toeopherol and the Beta-Carotene Cancer Prevention Study (ATBC)] will contribute 195 cases and 390 controls. Contractor will provide measurement of IGF-1, 1GFBP-3 and C-peptide in 661 plasma/serum samples (PLCO and ATBC: 195 multiple mycloma cases, 390 controls, and an additional 76 blinded quality control samples) and IGFBP-1 in 204 serum samples (ATBC only: 60 cases, 120 controls, 24 quality control samples). The period of performance for this procurement shall be for ten (10) months from date of award. The proposed contractor, Jewish General Hospital, Lady Davis Institute, Dr. Pollak’s Prevention Research laboratory has extensive experience in examining circulating levels of hormones and other analytes implicated with high assay precision. The lab is capable of measuring assays with high-throughput to analyze the needed number of samples for both the PLCO and ATBC studies. The laboratory measurements to be performed under this procurement are being performed as part of a multi-study pooling project (9 cohort studies in total) investigating these analytes. For scientific comparability and proprietary data and research in both the studies and the samples it is critical that the assays performed for all cohort studies participating in this pooling project be carried out at the same laboratory to assure standardized quality control procedures. The Jewish General Hospital, Lady Davis Institute, Dr. Pollak’s Prevention Research laboratory is the only source known to the NCI capable of providing the requested services. This is not a solicitation for competitive quotations. However, if any interested party believes it can meet the above requirement, they may submit a statement of capabilities. All information furnished shall be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI contracting office by 11:00 AM EST on August 14, 2009. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Ashley Virts, Contract Specialist at virtsa@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference NCI-90162-AV on all correspondence
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-90162-AV/listing.html)
- Record
- SN01898889-W 20090806/090805000512-acca8c80855004c70740bd8d5a5d4b8f (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |